Helen H. Sun

Discovery of a First-in-Class Receptor Interacting Protein 1 (RIP1) Kinase Specific Clinical Candidate (GSK2982772) for the Treatment of Inflammatory Diseases

Philip A. Harris, Scott B. Berger, Jae Uk Jeong et al. · Journal of Medicinal Chemistry · 2017 · 464 citations · Full text

Drug Target, Immunology, Cell Death +22

Discovery of Small Molecule RIP1 Kinase Inhibitors for the Treatment of Pathologies Associated with Necroptosis

Philip A. Harris, Deepak Bandyopadhyay, Scott B. Berger et al. · ACS Medicinal Chemistry Letters · 2013 · 135 citations · Full text

Pathologies Associated, Apoptosis, Immunology +24

The Identification and Pharmacological Characterization of 6-( <i>tert</i> -Butylsulfonyl)- <i>N</i> -(5-fluoro-1 <i>H</i> -indazol-3-yl)quinolin-4-amine (GSK583), a Highly Potent and Selective Inhibitor of RIP2 Kinase

Pamela A. Haile, Bartholomew J. Votta, Robert W. Marquis et al. · Journal of Medicinal Chemistry · 2016 · 122 citations · Full text

Identification of a RIP1 Kinase Inhibitor Clinical Candidate (GSK3145095) for the Treatment of Pancreatic Cancer

Philip A. Harris, Jill M. Marinis, John D. Lich et al. · ACS Medicinal Chemistry Letters · 2019 · 79 citations · Full text

Discovery and Lead-Optimization of 4,5-Dihydropyrazoles as Mono-Kinase Selective, Orally Bioavailable and Efficacious Inhibitors of Receptor Interacting Protein 1 (RIP1) Kinase

Philip A. Harris, Nicolas Faucher, Nicolas George et al. · Journal of Medicinal Chemistry · 2019 · 68 citations · Full text

Drug Target, Immunology, Efficacious Inhibitors +19